The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program

被引:81
作者
Shi, LZ
Thiebaud, P
McCombs, JS
机构
[1] Univ So Calif, Dept Pharmaceut Econ & Policy, Los Angeles, CA 90089 USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
misdiagnosis; bipolar disorders; suicide risk; costs; antidepressant;
D O I
10.1016/j.jad.2004.03.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: This study compares hospital use, suicide risk and health care costs of antidepressant patients with recognized bipolar disorders (recognized-BP) and unrecognized bipolar disorders (unrecognized-BP) with non-bipolar (non-BP) patients. Methods: Data from the California Medicaid (Medi-Cal) program were used to identify 25,460 adults with a new episode of antidepressant therapy. Recognized-BP? patients received either a bipolar (BP) diagnosis or a mood stabilizer (MS) on or before the initiation of antidepressant therapy. Unrecognized-BP patients received a BP diagnosis or MS therapy after antidepressant initiation. Non-BP patients had no BP diagnosis and no MS use. Multivariate models were used to estimate marginal risks and costs across groups. Results: Recognized-BP and unrecognized-BP represented 14.9% and 6.2% of all antidepressant users, respectively. Less than half of recognized-BP patients used a MS medication in conj. unction with their antidepressant. Unrecognized-BP patients were nearly four times more likely to attempt suicide and 50% more likely to be hospitalized than non-BP patients. Recognized-BP patients were at lower risk for attempted suicide and hospitalization relative to unrecognized-BP patients. Unrecognized-BP patients experienced higher 1-year total costs relative to non-BP patients (US$995, p<0.01) and recognized-BP patients (US$682, p<0.05). Limitations: Clinically relevant medical records data were not available making the classification of patients as unrecognized-BP, recognized-BP and non-BP imprecise. Conclusions: Unrecognized-BP is both common and costly. More than half of all recognized-BP patients do not use an MS at the time they initiated antidepressant therapy. More effort is needed to provide early and correct diagnosis and effectively treat both recognized-BP and unrecognized-BP patients. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:373 / 383
页数:11
相关论文
共 24 条
[1]   Validating antidepressant-associated hypomania (bipolar III):: a systematic comparison with spontaneous hypomania (bipolar II) [J].
Akiskal, HS ;
Hantouche, EG ;
Allilaire, JF ;
Sechter, D ;
Bourgeois, ML ;
Azorin, JM ;
Chatenêt-Duchêne, L ;
Lancrenon, S .
JOURNAL OF AFFECTIVE DISORDERS, 2003, 73 (1-2) :65-74
[2]   Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity? [J].
Akiskal, HS .
JOURNAL OF AFFECTIVE DISORDERS, 2003, 73 (1-2) :1-5
[3]   PHARMACOLOGICAL MANAGEMENT OF PREMENSTRUAL DISORDER [J].
ALTSHULER, LL ;
HENDRICK, V ;
PARRY, B .
HARVARD REVIEW OF PSYCHIATRY, 1995, 2 (05) :233-245
[4]  
Angst Jules, 2002, World Psychiatry, V1, P146
[5]  
Baldessarini RJ, 1999, AM J PSYCHIAT, V156, P811
[6]   Economic consequences of not recognizing bipolar disorder patients: A cross-sectional descriptive analysis [J].
Birnbaum, HG ;
Shi, LZ ;
Dial, E ;
Oster, EF ;
Greenberg, PE ;
Mallett, DA .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) :1201-1209
[7]  
*CAL MED ASS PROGR, 1998, ANN STAT REP CAL YEA
[8]  
GARVEY MJ, 1980, J CLIN PSYCHIAT, V41, P75
[9]   Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? [J].
Ghaemi, SN ;
Sachs, GS ;
Chiou, AM ;
Pandurangi, AK ;
Goodwin, FK .
JOURNAL OF AFFECTIVE DISORDERS, 1999, 52 (1-3) :135-144
[10]   Effectiveness and safety of long-term antidepressant treatment in bipolar disorder [J].
Ghaemi, SN ;
Lenox, MS ;
Baldessarini, RJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (07) :565-569